Lechner-Scott, J., Spencer, B., Girard, M., Grammond, P., Oreja-Guevara, C., Hupperts, R., Bergamaschi, R., Boz, C., Giuliani, G., Van Pesch, V., Iuliano, G., Fiol, M., De Malmanche, T., , , , , , , , , , , Attia, J.R., , , , , Fitzgerald, M., Trojano, M., Grand'Maison, F., Antonio C Gomez, J., Izquierdo, G., Duquette, P.. Sage; 2012. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude.

Malhotra, S., Morcillo-Suárez, C., Chan, A., Vandenbroeck, K., Navarro, A., Bustamante, M. F., Rio, J., Akkad, D. A., Giacalone, G., Sánchez, A. J., Leyva, L., Alvarez-Lafuente, R., Brassat, D., Zettl, U. K., Oksenberg, J., Montalban, X., Comabella, M., Goertsches, R., Lechner-Scott, J., Urcelay, E., Fernández, O., Drulovic, J., García-Merino, A., Boneschi, F. Martinelli. Elsevier; 2011. IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis.

Verheul, F., Smolders, J., Comi, G., Izquierdo, G., Grammond, P., Lus, G., Petersen, T., Bergamaschi, R., Giuliani, G., Boz, C., Coniglio, G., Van Pesch, V., Trojano, M., Lechner-Scott, J., Cavalla, P., Granella, F., Avolio, C., Fiol, M., Poehlau, D., Saladino, M. L., Gallo, P., Deri, N., Oleschko Arruda, W., Lepore, V., Paine, M., Ferro, M., Barnett, M., Cabrera-Gomez, J. A., Slee, M., Moore, F., Shaw, C., Petkovska-Boskova, T., Rutherford, M., Engelsen, O., Zwanikken, C., Damoiseaux, J., Hupperts, R., Amato, M. P., Grand'Maison, F., Butzkueven, H., Marrosu, M., Duquette, P.. Wiley-Blackwell Publishing; 2013. Fluctuations of MS births and UV-light exposure.

The International Multiple Sclerosis Genetics Consortium, Esposito, F., Patsopoulos, N. A., Lechner-Scott, J., Goris, A., Dobosi, R., Dubois, B., Rioux, J. D., Oturai, A. B., Sondergaard, H. B., Sellebjerg, F., Sorensen, P. S., Reunanen, M., Cepok, S., Koivisto, K., Cournu-Rebeix, I., Fontaine, B., Winkelmann, J., Gieger, C., Infante-Duarte, C., Zipp, F., Bergamaschi, L., Leone, M., Bergamaschi, R., Kockum, I., Cavalla, P., Lorentzen, A. R., Mero, I. L., Celius, E. G., Harbo, H. F., Spurkland, A., Comabella, M., Brynedal, B., Alfredsson, L., Bernardinelli, L., Leppa, V., Robertson, N. P., Hawkins, C. P., Barcellos, L. F., Beecham, G., Bush, W., Cree, B. A. C., Daly, M. J., Ivinson, A. J., Aubin, C., Compston, A., Booth, D. R., D'Alfonso, S., Haines, J. L., Hauser, S. L., Hemmer, B., Hillert, J., McCauley, J. L., Oksenberg, J., Olsson, T., Palotie, A., Peltonen, L., Heard, R. N., Pericak-Vance, M. A., Saarela, J., Sawcer, S. J., Stranger, B., Boneschi, F. M., Comi, G., Hafler, D. A., de Bakker, P. I. W., De Jager, P. L., Stewart, G. J., Cox, M., Scott, R. J.. Nature Publishing Group; 2010. IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.

Caruana, P., Lemmert, K., Ribbons, K., Lea, R., Lechner-Scott, J.. Sage; 2017. Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.

Lorscheider, J., Kuhle, J., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Trojano, M., Ramo-Tello, C., Lechner-Scott, J., Pucci, E., Solaro, C., Slee, M., Izquierdo, G., Van Pesch, V., Sanchez Menoyo, J. L., van der Walt, A., Butzkueven, H., Kappos, L., Kalincik, T., Lugaresi, A., Havrdova, E., Horakova, D., Hupperts, R., Duquette, P., Girard, M., Prat, A.. Wiley-Blackwell Publishing; 2019. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Simpson, S., Tan, H., Williams, D., van der Mei, I., Ausimmune/AusLong Investigators Group,, Otahal, P., Taylor, B., Ponsonby, A.-L., Lucas, R. M., Blizzard, L., Valery, P. C., Lechner-Scott, J., Shaw, C.. Wiley-Blackwell Publishing; 2016. Anxiety, depression and fatigue at 5-year review following CNS demyelination.

Saul, A., Taylor, B. V., Lechner-Scott, J., van der Mei, I., Blizzard, L., Simpson-Yap, S., Oddy, W. H., Shivappa, N., Hebert, J. R., Black, L. J., Ponsonby, A. L., Broadley, S. A.. Elsevier; 2024. A pro-inflammatory diet is associated with long-term depression and anxiety levels but not fatigue in people with multiple sclerosis.

O'Gorman, C., Freeman, S., Kilpatrick, T. J., Lechner-Scott, J., Moscato, P., Perreau, V. M., Scott, R. J., Stankovich, J., Stewart, G. J., Chapman, C., Marriot, M., Tanner, M., Taylor, B. V., Tubridy, N., Wiley, J., Butzkueven, H., Broadley, S. A., Bahlo, M., Booth, D. R., Brown, M. A., Foote, S. J., Griffiths, L. R.. BMJ Group; 2011. Familial recurrence risks for multiple sclerosis in Australia.

Ramanathan, S., Fraser, C., Curnow, S. R., Ghaly, M., Leventerg, R. J., Lechner-Scott, J., Henderson, A., Reddel, S., Daled, R. C., Brilot, F.. Wiley-Blackwell; 2019. Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity.

Ban, M., McCauley, J. L., Dudbridge, F., Wason, J., Robertson, N. P., De Jager, P. L., Hafler, D. A., Barcellos, L. F., Ivinson, A. J., Sexton, D., Oksenberg, J. R., Hauser, S. L., Zuvich, R., Pericak-Vance, M. A., Haines, J., Compston, A., Sawcer, S., Baker, A., Bergamaschi, L., Cox, M., Kemppinen, A., D'Alfonso, S., Guerini, F. R., Lechner-Scott, J.. Nature Publishing Group; 2010. A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis.

Bhandari, A., Xiang, H., Lechner-Scott, J., Agzarian, M.. Elsevier; 2020. Central vein sign for multiple sclerosis: a systematic review and meta-analysis.

Graves, M. C., Benton, M., Lea, R. A., Boyle, M., Tajouri, L., Macartney-Coxson, D., Scott, R. J., Lechner-Scott, J.. Sage; 2014. Methylation differences at the HLA-DRB1 locus in CD4+ T-Cells are associated with multiple sclerosis.

Saul, A., Taylor, B. V., van der Mei, I., Ausimmune/AusLong Investigators Group,, Blizzard, L., Simpson-Yap, S., Oddy, W. H., Probst, Y. C., Black, L. J., Ponsonby, A. L., Broadley, S. A., Lechner-Scott, J.. Elsevier; 2023. Higher dietary quality is prospectively associated with lower MRI FLAIR lesion volume, but not with hazard of relapse, change in disability or black hole volume in people with Multiple Sclerosis.

Lefort, M., Sharmin, S., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Andersen, J. B., Gout, O., Lechner-Scott, J., .,, .,, .,, .,, .,, .,, .,, .,, Vukusic, S., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Casey, R., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Debouverie, M., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Edan, G., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Ciron, J., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Ruet, A., .,, .,, .,, .,, .,, .,, .,, .,, De Sèze, J.. BioMed Central; 2022. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

Saul, A., Taylor, B. V., van der Mei, I., Blizzard, L., Simpson-Yap, S., Oddy, W. H., Probst, Y. C., Black, L. J., Ponsonby, A. L., Broadley, S. A., Lechner-Scott, J.. Elsevier; 2022. Associations between diet quality and depression, anxiety, and fatigue in multiple sclerosis.

Lechner-Scott, J., Kerr, T., Spencer, B., Agland, S., Lydon, A., Schofield, P. W.. Sage Publications; 2010. The audio recorded cognitive screen (ARCS) in patients with multiple sclerosis: a practical tool for multiple sclerosis clinics.

Mahurkar, S., Moldovan, M., Jokubaitis, V. G., McKay, F. C., Gatt, P. N., Fabis-Pedrini, M. J., Martinelli, V., Comi, G., Lechner-Scott, J., Kermode, A. G., Slee, M., Taylor, B. V., Suppiah, V., , , , , Sorosina, M., Clarelli, F., Liberatore, G., Malhotra, S., Montalban, X., Antigüedad, A., Krupa, M.. Nature Publishing Group; 2017. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.

Gray, O. M., Jolley, D., Lechner-Scott, J., Zwanikken, C., Trojano, M., Grand'Maison, F., Duquette, P., Grammond, P., Bergamaschi, R., Giuliani, G., Taffi, R.. Association of South East Asian Nations, Neurological Association; 2008. The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases five years after onset of multiple sclerosis.

Hardy, T. A., Aouad, P., Lee, A., Malhotra, R., Mccombe, P., Parratt, J., Plummer, C., Van Der Walt, A., Martel, K., Walker, R. A., Barnett, M. H., Blum, S., Broadley, S., Carroll, W. M., Crimmins, D., Griffiths, D., Hodgkinson, S., Lechner-Scott, J.. Sage; 2024. Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.

Spelman, T., Mekhael, L., Grammond, P., Barnett, M., Lechner-Scott, J., Alroughani, R., Trojano, M., Lugaresi, A., Granella, F., Pucci, E., Vucic, S., Burke, T., Butzkueven, H., Hodgkinson, S., Havrdova, E., Horakova, D., Duquette, P., Izquierdo, G., Grand'Maison, F.. Wiley-Blackwell Publishing; 2016. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.

Bergamaschi, R., Montomoli, C., Boz, C., Iuliano, G., Zwanikken, C., Petersen, T., Lechner-Scott, J., Hupperts, R., Butzkueven, H., Pucci, E., Oreja-Guevara, C., Cristiano, E., Mallucci, G., Pia Amato, M. P., Havrdova, E., Fernandez-Bolanos, R., Spelman, T., Trojano, M., Lugaresi, A., Izquierdo, G., Grand'Maison, F., Duquette, P., Shaygannejad, V., Alroughani, R., Grammond, P.. Wiley-Blackwell; 2015. BREMSO: a simple score to predict early the natural course of multiple sclerosis.